๐Ÿ”Ž Trials Near Me

Home โ€บ Migraine โ€บ New York

Migraine clinical trials in New York

16 studies for Migraine are looking for participants at sites in New York.

Cities in New York

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

  • Nuvance Health Institute, Kingston
  • Northwell Health, Manhasset
  • Mt Sinai Icahn School of Medicine, New York
RecruitingPhase 4
Ages 18 to 70 ยท All sexes ยท Updated Nov 13, 2026 ยท NCT06972056

Study of EVO756 in Adults With Migraine

  • Clinosis - Dent Neurologic Instite, Amherst
RecruitingPhase 2
Ages 18 to 64 ยท All sexes ยท Updated Nov 13, 2026 ยท NCT07616128

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  • Dent Neuro Institute, Buffalo, Amherst
  • SPRI Clinical Trials, LLC, Brooklyn
  • True North Neurology, Commack
  • and 4 more
RecruitingPhase 3
Ages 18 to 75 ยท All sexes ยท Updated Nov 2, 2026 ยท NCT07645924

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  • Dent Neurosciences Research Center, Amherst
  • True North Neurology, Commack
  • New York Neurology Associates, New York
RecruitingPhase 3
Ages 6 to 17 ยท All sexes ยท Updated Oct 27, 2026 ยท NCT04743141

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  • Dent Neurosciences Research Center, Amherst
  • True North Neurology, Commack
  • Northwell Health IRB, Great Neck
  • and 4 more
RecruitingPhase 3
Ages 6 to 17 ยท All sexes ยท Updated Oct 27, 2026 ยท NCT04649242

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

  • Montefiore Medical Center, The Bronx
RecruitingPhase 3
Ages 6 to 17 ยท All sexes ยท Updated Oct 14, 2026 ยท NCT05156398

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

  • True North Neurology - Commack (North Suffolk Neurology), Commack
RecruitingPhase 3
Ages 6 to 17 ยท All sexes ยท Updated Oct 14, 2026 ยท NCT05164172

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

  • Dent Neurologic Institute - Amherst /ID# 270260, Amherst
RecruitingPhase 3
Ages 12 to 17 ยท All sexes ยท Updated Oct 9, 2026 ยท NCT06810505

RELAXaHEAD for Headache Patients (Phase III)

  • NYU Langone Health, New York
Recruiting
Ages 16 to 80 ยท All sexes ยท Updated Oct 8, 2026 ยท NCT06077838

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

  • Columbia University Irving Medical Center - NewYork Presbyterian Hospital (CUIMC/NYP), New York
RecruitingPhase 3
Ages 18 to 55 ยท All sexes ยท Updated Oct 8, 2026 ยท NCT07629635

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

  • True North Neurology, Port Jefferson Station
RecruitingPhase 1
Ages 6 to 11 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT06995729

A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache

  • Maimonides Medical Center, Brooklyn
RecruitingPhase 4
Ages 18 to 65 ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06473597

Responding With Evidence and Access for Childhood Headaches

  • Dent Neurological Institute, Amherst
Recruiting
Ages 10 to 17 ยท All sexes ยท Updated Sep 21, 2026 ยท NCT05889624

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

  • Dent Neurologic Institute - Amherst /ID# 231182, Amherst
  • SUNY Upstate Medical University /ID# 239898, Syracuse
RecruitingPhase 3
Ages 6 to 17 ยท All sexes ยท Updated Sep 14, 2026 ยท NCT05125302

Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines

  • Neuroscience Institute at Great Neck, Great Neck
RecruitingPhase 2
Ages 18 to 75 ยท All sexes ยท Updated May 22, 2026 ยท NCT07061847

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.